文献速递肝病

NAFLD患者择期冠脉造影时血清生物标志物与动脉粥样硬化性心血管病的关联

Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-08-28

本研究前瞻性纳入619例接受择期冠脉造影的患者(65%合并NAFLD),评估心脏生物标志物与严重CAD风险的关联。结果显示NAFLD患者中严重CAD或高风险者hs-cTnI水平更高,且hs-cTnI与CAD风险独立相关。hs-cTnI可能有助于NAFLD患者的CAD风险预测。

要点

  • NAFLD患者中严重CAD或CAD高风险者hs-cTnI水平显著高于NAFLD对照。
  • hs-cTnI升高与严重CAD或CAD风险增加相关,NAFLD患者中OR为2.3和2.2。
  • hs-cTnI可能作为NAFLD患者CAD风险预测的候选标志物,有待验证。

核心结论

  • 在NAFLD患者中,高hs-cTnI与严重CAD或CAD风险增加相关,可能有助于CAD风险预测。

研究设计与样本

  • 前瞻性队列研究,纳入619例接受择期冠脉造影的患者,平均年龄63±10岁,80%男性,31%合并2型糖尿病,65%合并NAFLD。

主要发现

  • 合并NAFLD且存在严重CAD(44%)或CAD风险(58%)的患者hs-cTnI水平高于NAFLD对照(均P < .001)。
  • 全部患者中严重CAD或CAD风险与年龄较大、男性、代谢综合征组分及hs-cTnI升高相关,OR分别为2.0(95%CI 1.4-2.9)和1.8(95%CI 1.1-3.0)。
  • NAFLD患者中严重CAD或CAD风险与hs-cTnI升高的OR分别为2.3(95%CI 1.4-3.8)和2.2(95%CI 1.2-4.2)(均P < .02)。
  • 合并与不合并严重CAD的患者NAFLD患病率相似(68% vs 62%;P > .05)。

关键数值与推荐

  • 严重CAD定义为至少1支近端动脉狭窄>70%。
  • CAD风险定义为存在严重CAD或动脉粥样硬化性心血管病评分≥20。
  • NAFLD定义为存在肝脂肪且无其他肝病。

临床怎么用

  • 对NAFLD患者可考虑检测hs-cTnI以辅助CAD风险分层,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cardiovascular disease is the most common cause of death among patients with nonalcoholic fatty liver disease (NAFLD). We assessed select cardiac biomarker associations for existing or future coronary artery disease (CAD) risk in patients with NAFLD. METHODS: Patients with/without NAFLD undergoing elective cardiac angiography were prospectively enrolled. Severe CAD was defined as presence of at least 1 proximal artery >70% stenosis; risk of severe CAD as either existing severe CAD or atherosclerotic cardiovascular disease score ≥20; NAFLD was defined as hepatic fat in the absence of other liver diseases. Cardiac biomarkers (high-sensitivity C-reactive protein, N-terminal pro-brain natriuretic peptide, and high-sensitivity cardiac troponin I [hs-cTnI]) were measured using Atellica Solution assays (Siemens Healthineers). RESULTS: A total of 619 patients were enrolled (mean age, 63 ± 10 years; 80% male; 31% type 2 diabetes; 65% NAFLD); 42% had severe CAD, and 57% had risk of severe CAD. NAFLD prevalence was similar between patients with and without severe CAD (68% vs 62%; P > .05). Patients with NAFLD with severe CAD (44%) or with risk of severe CAD (58%) had higher levels of hs-cTnI than NAFLD controls (both P < .001). Presence of severe CAD or risk of severe CAD in all patients was associated with older age, male, aspects of metabolic syndrome, and elevated hs-cTnI: odds ratio 2.0 (95% confidence interval [CI],1.4-2.9) and 1.8 (95% CI, 1.1-3.0), respectively; 2.3 (95% CI, 1.4-3.8) and 2.2 (95% CI, 1.2-4.2), respectively, in patients with NAFLD (all P < .02). CONCLUSION: CAD is common in patients with NAFLD. High hs-cTnI was associated with an increased risk of CAD. Pending validation, hs-cTnI may be a useful marker for CAD risk prediction in patients with NAFLD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Felix S, Jeffers T, et al. Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. Clin Gastroenterol Hepatol. 2021. PMID: 34464720. doi:10.1016/j.cgh.2021.08.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。